Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS^G12C mutations.

IF 3.1 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-09-16 DOI:10.1080/14796694.2026.2719409

Fabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, Ludovic Doucet, Aitor Azkárate Martínez, Vanesa Gregorc, Oscar Juan-Vidal, Shun Lu, Charlotte De Bondt, Filippo de Marinis, Helena Linardou, Young-Chul Kim, Robert Jotte, Enriqueta Felip, Giuseppe Lo Russo, Martin Reck, Mary F MichenzIe, Wenjing Yang, Julie N Meade, Beata Korytowsky, Tony S K Mok

引用次数: 0

查看原文本刊更多论文

KRYSTAL-12研究结果的简明语言总结：阿达格拉西用于KRASG12C突变的非小细胞肺癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.

Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations.

Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS^G12C mutations.